Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Feb;14(2):157-159.
doi: 10.1016/j.jtho.2018.11.006. Epub 2018 Dec 28.

Does Chromothripsis Make Mesothelioma an Immunogenic Cancer?

Michele Carbone  1 , Haining Yang  2 , Giovanni Gaudino  2
Affiliations
Editorial

Does Chromothripsis Make Mesothelioma an Immunogenic Cancer?

Michele Carbone et al. J Thorac Oncol. 2019 Feb.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Chromothripsis and tumor development. DNA damage may lead to the formation of micronuclei, extranuclear structures containing a single chromosome, surrounded by a nuclear membrane. During the interphase, the micronuclei membrane disrupts leading to chromosome shattering because the DNA is fragmented by exposure to cytoplasmic nucleases. The resulting chromosome fragments –or some of them- can be re-localized in the nuclei during subsequent mitoses and re-ligated at random by the non-homologous-end-joint (NHEJ) repair system. This process, known as chromothripsis, generates aberrant chromosomes with complex, random, rearrangements, leading to a very high number of genetic alterations within a few cell cycles, and to the possible emergence of malignant cell clones.
See this image and copyright information in PMC

Comment on

  • Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma.
    Mansfield AS, Peikert T, Smadbeck JB, Udell JBM, Garcia-Rivera E, Elsbernd L, Erskine CL, Van Keulen VP, Kosari F, Murphy SJ, Ren H, Serla VV, Schaefer Klein JL, Karagouga G, Harris FR, Sosa C, Johnson SH, Nevala W, Markovic SN, Bungum AO, Edell ES, Dong H, Cheville JC, Aubry MC, Jen J, Vasmatzis G. Mansfield AS, et al. J Thorac Oncol. 2019 Feb;14(2):276-287. doi: 10.1016/j.jtho.2018.10.001. Epub 2018 Oct 10. J Thorac Oncol. 2019. PMID: 30316012 Free PMC article.

References

    1. Mansfield AS, Peikert T, Smadbeck JB, et al. Neoantigenic potential of complex chromosomal rearrangements in mesothelioma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2018. - PMC - PubMed
    1. Guo G, Chmielecki J, Goparaju C, et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer research 2015;75:264–269. - PubMed
    1. Bueno R, Stawiski EW, Goldstein LD, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nature genetics 2016;48:407–416. - PubMed
    1. Aypar U, Smoley SA, Pitel BA, et al. Mate pair sequencing improves detection of genomic abnormalities in acute myeloid leukemia. European journal of haematology 2018. - PMC - PubMed
    1. Carbone M, Kanodia S, Chao A, et al. Consensus Report of the 2015 Weinman International Conference on Mesothelioma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016;11:1246–1262. - PMC - PubMed